NCT01895270View on ClinicalTrials.gov

Improving Buprenorphine Detoxification Outcomes With Isradipine

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Opioid Dependence
Interventions
DRUG

Isradipine

Isradipine extended release formulation

DRUG

Placebo

Placebo will consist of microcrystalline cellulose.

Trial Locations (1)

72205

UAMS Psychiatric Research Institute, Little Rock

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

University of Arkansas

OTHER

NCT01895270 - Improving Buprenorphine Detoxification Outcomes With Isradipine | Biotech Hunter | Biotech Hunter